Navigation Links
GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets,Phase II Study Endpoints of Immunogenicity and Safety Compared to,Licensed Vaccines

Y-TT Vaccine Study

The Phase II study evaluated the immune response and safety of Hib-MenCY-TT compared to a licensed monovalent Hib conjugate vaccine (ActHib® Haemophilus influenza type b Conjugate Vaccine Tetanus Toxoid Conjugate) in infants and to a licensed polysaccharide meningococcal ACWY vaccine (Menomune® Meningococcal Polysaccharide Vaccine, Serogroups A, C, Y and W-135 Combined) in children 3-5 years of age.

In this single-blind, Phase II study, 609 infants were randomized 1:1 to receive either Hib-MenCY-TT or licensed Hib vaccine at 2, 4, and 6 months concomitantly with DTaP-Hep B-IPV (Pediarix®Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Combined) and pneumococcal 7-valent conjugate vaccine (Prevnar® Pneumococcal 7-valent Conjugate Vaccine Diphtheria CRM Protein). A second control group of 150 children 3-5 years of age received one dose of Neisseria meningitidis serogroups A, C, W-135 and Y polysaccharide vaccine with no co-administered vaccines. Serologic follow-up was conducted one month after dose 3 of Hib-MenCY-TT/Hib or one month after ACWY, and safety follow-up was conducted from enrollment in the study until 31 days after dose 3 in the Hib-MenCY-TT/Hib groups and 31 days after vaccination in the ACWY group. The primary safety follow-up period of interest was defined as the four days immediately following each vaccination.

Results from the study are:

  • Hib immune response induced by the Hib-MenCY-TT combination vaccine was non-inferior and statistically significantly higher than the monovalent Hib vaccine (93.5% anti-PRP ? 1 mcg/mL vs. 85.8% PRP ? 1 mcg/mL, respectively).
  • The Hib-MenCY-TT combination vaccine induced antibodies nea
    '"/>





Page: 1 2 3 4 5

Related medicine technology :

1. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
2. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
3. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
4. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
5. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
6. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
7. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
8. Intarcia Therapeutics Announces Presentation of Final Results From a Phase 2 Combination Study for the Treatment of Hepatitis C at the Digestive Disease Week Conference
9. Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure as Long-Term Monotherapy and in Combination Therapy
10. King Pharmaceuticals Reports Efficacy of Altace 20mg And Efficacy of a Combination of Altace 20mg And Hydrochlorothiazide 25mg For 24-hour Blood Pressure Control
11. King Pharmaceuticals Announces Plan to Present Results from Phase III Clinical Trial Evaluating ALTACE as Monotherapy and in Combination with Hydrochlorothiazide at the American Society of Hypertension Annual Meeting
Post Your Comments:
(Date:10/6/2008)...proved Pharmacokinetic Characteristics of Naltrexo...bility in Clinical Trials -, PHOENIX, Oct. 6 /PRN...(Nasdaq: OREX ), a biopharmaceutical company focu...nervous system-related disorders, today presented,... (naltrexone SR /,bupropion SR), successfully achi...
(Date:10/6/2008)...SEATTLE, Oct. 6 /- Dendreon... call today, Monday, October 6, 2008 at 9:00 AM,ET... analysis of its IMPACT,(IMmunotherapy for Prostat...clinical trial of PROVENGE(R) (sipuleucel-T), the ...erapy for the treatment of advanced prostate,cance...
(Date:10/6/2008)...Recent study revealed that drinking polyphenol-ric... changes in appetite, energy intake or body,weight...consumption of 100%,polyphenol-rich Concord grape ...ot associated with changes in appetite and was sho...data presented at the 49th Annual Meeting of,the A...
(Date:10/3/2008)...Burlington County, New Jersey is the newest study .../ -- The Children,s Hospital,of Philadelphia today... The,National Children,s Study. Children,s Hospita... data collection in Burlington County, New,Jersey.... Health., Investigators anticipate approximately ...
Breaking Medicine Technology:Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 2Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 3Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 4Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 5Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 2Concord Grape Juice Has No Significant Impact on Body Weight 2Concord Grape Juice Has No Significant Impact on Body Weight 3The Children's Hospital of Philadelphia Announces New Regional Participant in The National Children's Study 2FDA Demands Tougher Warnings on Immunosuppressive Drugs 26079 1FDA Demands Tougher Warnings on Immunosuppressive Drugs 26079 2FDA Demands Tougher Warnings on Immunosuppressive Drugs 26079 3Schofield Publishing Enters the Newsletter Market 26074 1Schofield Publishing Enters the Newsletter Market 26074 2VIDEO from Medialink and Kelloggs 3A Its All in the Jeans 26068 1Study 3A Delaying evolution of drug resistance in malaria parasite possible 26064 1Study 3A Delaying evolution of drug resistance in malaria parasite possible 26064 2Study 3A Delaying evolution of drug resistance in malaria parasite possible 26064 3
...WIRE)--Jul 3, 2007 - EPIX,Pharmaceuticals, Inc. (N...an, M.D., Ph.D., chief executive officer of EPIX, ...bin Emerging Growth,Opportunities Conference on Tu...darin Oriental Hotel in New York, NY., The present...the,EPIX website, www.epixpharma.com, in the inves...
...Jul 2, 2007 - Metabasis Therapeutics,(NASDAQ:MBRX)...very, development and commercialization of novel d...ases by targeting the liver,and liver pathways, an...t of finance and chief financial officer of Metaba...rging Growth Opportunities,Conference at the Manda...
Other Medicine Technology:EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin,Emerging Growth Opportunities Conference 2Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth,Conference and Attend Pacific Growth Equities Conference 2
(Date:10/6/2008)...t against childhood obesity, researcher notes , ...ee-quarters of middle schools have vending machine...study finds. , The research demonstrates that t...and "that those vending machines don,t always have...rus, a registered dietitian with the Center for Ob...
(Date:10/6/2008)...wire-FirstCall/ -- HealthSouth,Corporation (NYSE: ...ly,publicized investor meeting in New York City. P...30 a.m. EST at the Grand Hyatt New York, located a... follows:, 8:00 a.m. Continental Breakfast 8...ive Officer -- HealthSouth Overview a...
(Date:10/6/2008)...nel and their family members can take,anonymous on...STON, Oct. 6 /PRNewswire-USNewswire/ -- Military l...their families that are unique and,difficult. Some...atters get,worse and one problem can trigger other...check things out to see what is really happening.,...
(Date:10/6/2008)...University of California, San Diego School of Medi...ts bolsters production of a protective chemical no...n infections that are a common result of atopic de...study led by Richard Gallo, M.D., Ph.D., professo...logy at the UCSD School of Medicine and the Dermat...
Breaking Medicine News(10 mins):Health News:Vending Machines Found in Most Middle Schools 2Health News:HealthSouth to Hold Investor Meeting November 10, 2008 2Health News:Many Military Installations Worldwide Participate in National Depression Screening Day 2Health News:Many Military Installations Worldwide Participate in National Depression Screening Day 3Health News:Oral vitamin D may help prevent some skin infections 2
... fractures linked to osteoporosis without the need...ifornia have been looking at the effect of a new t...ients with osteoporosis. They injected an acrylic ...rly done during surgery. Two weeks later//, many p...
...ly detection of all forms of cancer has been devel...lesterol test, the 'C-Test' will be evaluated in a...hs. It is based on scientific work by the John Bas...t the Engalnd National University. Professor Rodri...
... of the potentially fatal condition pre-eclampsia ...The study, published in the Lancet, found that tak...g pre-eclampsia. The condition involves the pregn...can interfere with the feeding of the unborn child...
...echnology will provide the most effective defence ...genome project, and developments in understanding...in developing tests and vaccines that will protect...- as well as natural epidemics.// The annual meeti...
Other Medicine News:Health News:Detection of Cancer 2Health News:Biotechnology on the lead 2
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
Medicine Products: